이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Cybin 관리

관리 기준 확인 4/4

Cybin's CEO는 Doug Drysdale, Nov2020 에 임명되었습니다 의 임기는 3.58 년입니다. 총 연간 보상은 CA$ 834.17K, 79.3% 로 구성됩니다. 79.3% 급여 및 20.7% 보너스(회사 주식 및 옵션 포함). 는 $ 10.34K 가치에 해당하는 회사 주식의 0.005% 직접 소유합니다. 10.34K. 경영진과 이사회의 평균 재임 기간은 각각 3.6 년과 3.6 년입니다.

주요 정보

Doug Drysdale

최고 경영자

CA$834.2k

총 보상

CEO 급여 비율	79.3%
CEO 임기	3.7yrs
CEO 소유권	0.005%
경영진 평균 재임 기간	3.7yrs
이사회 평균 재임 기간	3.7yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Doug Drysdale 의 보수는 Cybin 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-CA$78m
Dec 31 2023	n/a	n/a	-CA$70m
Sep 30 2023	n/a	n/a	-CA$51m
Jun 30 2023	n/a	n/a	-CA$49m
Mar 31 2023	CA$834k	CA$662k	-CA$47m
Dec 31 2022	n/a	n/a	-CA$52m
Sep 30 2022	n/a	n/a	-CA$58m
Jun 30 2022	n/a	n/a	-CA$66m
Mar 31 2022	CA$3m	CA$549k	-CA$68m
Dec 31 2021	n/a	n/a	-CA$63m
Sep 30 2021	n/a	n/a	-CA$58m
Jun 30 2021	n/a	n/a	-CA$43m
Mar 31 2021	CA$2m	CA$277k	-CA$32m

보상 대 시장: Doug 의 총 보상 ($USD 608.53K ) US 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 1.62M ).

보상과 수익: Doug 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Doug Drysdale (54 yo)

3.7yrs

테뉴어

CA$834,173

보상

Mr. Douglas L. Drysdale, also known as Doug, is Chief Executive Officer at Cybin, Inc. since November 05, 2020. Mr. Drysdale serves as the Member of Board of Directors for SpineThera, Inc. from May 2022. H...

리더십 팀

이름	위치	테뉴어	보상	소유권
Eric So	Co-Founder	3.7yrs	CA$624.00k	1.52% CA$ 3.1m
Douglas Drysdale	Chief Executive Officer	3.7yrs	CA$834.17k	0.0050% CA$ 10.3k
Paul Glavine	Co-Founder	no data	CA$624.00k	1.48% CA$ 3.0m
Greg Cavers	Chief Financial Officer	3.7yrs	CA$329.20k	0.0053% CA$ 10.8k
Aaron Bartlone	Chief Operating Officer	less than a year	CA$515.53k	0.092% CA$ 190.0k
John Kanakis	Co-Founder	no data	CA$1.49m	데이터 없음
Alex Nivorozhkin	Chief Scientific Officer	3.6yrs	데이터 없음	0.69% CA$ 1.4m
Lori Challenger	Chief Compliance	2.8yrs	데이터 없음	데이터 없음
Gabriel Fahel	Chief Legal Officer & Corporate Secretary	3.7yrs	데이터 없음	0.038% CA$ 78.0k
Sara Somerset	Chief Communications Officers	no data	데이터 없음	데이터 없음
James Andrews	Chief Cultivation & Extraction Officer	no data	데이터 없음	데이터 없음
Domenico Fuoco	Senior Vice President of Scientific Innovation	no data	데이터 없음	데이터 없음

3.7yrs

평균 재임 기간

50.5yo

평균 연령

경험이 풍부한 관리: CYBN 의 관리팀은 경험 ( 3.6 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Eric So	Co-Founder	3.7yrs	CA$624.00k	1.52% CA$ 3.1m
Paul Glavine	Co-Founder	3.7yrs	CA$624.00k	1.48% CA$ 3.0m
George Tziras	Chief Business Officer & Director	less than a year	데이터 없음	0.17% CA$ 350.9k
Theresa Firestone	Lead Independent Director	2.9yrs	CA$65.00k	0.0053% CA$ 10.9k
Mark Lawson	Independent Director	3.7yrs	CA$50.00k	0.015% CA$ 31.2k
Grant Froese	Independent Director	3.7yrs	CA$50.00k	데이터 없음
Eric Hoskins	Independent Director	3.7yrs	CA$50.00k	0.013% CA$ 27.1k

3.7yrs

평균 재임 기간

51yo

평균 연령

경험이 풍부한 이사회: CYBN 의 이사회는 경험(평균 재직 기간 3.6 년)으로 간주됩니다.

Cybin 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

Co-Founder recently bought US$64k worth of stock

Cybin Inc. Appoints Atul R. Mahableshwarkar as Senior Vice President, Clinical Development

Cybin Inc. Announces Appointment of Aaron Bartlone as Chief Operating Officer, Effective July 1, 2023

Cybin Inc., Annual General Meeting, Aug 29, 2023

Cybin Announces Scientific Management Transition

High number of new and inexperienced directors

Recent updates

Co-Founder recently bought US$64k worth of stock

No longer forecast to breakeven

Cybin Inc. Appoints Atul R. Mahableshwarkar as Senior Vice President, Clinical Development

Forecast to breakeven in 2027

Cybin Inc. announced that it has received $150 million in funding from a group of investors

New minor risk - Profitability

Cybin Inc. Initiates Phase 2 Proof-Of-Concept Study of Cyb004 in Generalized Anxiety Disorder

Cybin Inc. Receives FDA Breakthrough Therapy Designation for Its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder

Cybin Inc. Announces Positive End-Of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design

Cybin Inc. announced that it expects to receive $150 million in funding from a group of investors

Cybin Announces FDA Clearance to Initiate a Phase 2a Study of CYB004 in Generalized Anxiety Disorder

Cybin Inc. Announces Positive Topline Data from Phase 1 Studies of Proprietary Deuterated DMT Molecules CYB004 and SPL028

Cybin Inc. Announces the Presentation of Four Posters At the American College of Neuropsychopharmacology Annual Meeting

Cybin Inc. Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses

Cybin Inc. has completed a Composite Units Offering in the amount of $30 million.

New major risk - Revenue and earnings growth

Cybin Inc. Announces Unprecedented Positive Phase 2 Interim Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose

Cybin Inc. completed the acquisition of Small Pharma Inc. (TSXV : DMT).

New major risk - Shareholder dilution

Cybin Inc. Completes Enrollment in Phase 2 Study of CYB003 in Major Depressive Disorder

Cybin Inc. agreed to acquire Small Pharma Inc. (TSXV : DMT) for $23.2 million.

Cybin Inc. Prepares for GMP Manufacturing of CYB003 Capsules for Phase 3 Trial

New major risk - Financial position

Cybin Inc. has completed a Composite Units Offering in the amount of $8.25 million.

Cybin Inc. Announces Phase 2 Cohort 5 Dosing Completion of Cyb003 in Major Depressive Disorder

Cybin Inc. Announces Publication of Sponsored Feasibility Study Validating Kernel's Flow1 Neuroimaging Technology Measuring Psychedelic Effects on the Brain

Cybin Inc. Announces the Development of Scalable Psychedelic Facilitation Training Program, Embarkct

New minor risk - Share price stability

Cybin Inc. Announces Appointment of Aaron Bartlone as Chief Operating Officer, Effective July 1, 2023

Cybin Inc., Annual General Meeting, Aug 29, 2023

Cybin Announces Scientific Management Transition

Cybin Inc. announced that it expects to receive CAD 41 million in funding from Lincoln Park Capital, LLC

Cybin Inc. Initiates First-In-Human Dosing of CYB004 in Phase 1 Clinical Trial

Cybin Inc. Announces Last Subject Dosed in Part B of Its Phase 1 CYB004-E Trial

Cybin Announces Approval of First-in-Human Dosing of its Proprietary DMT Molecule CYB004

Cybin Inc. Announces Promising Results from Sponsored Kernel Flow Feasibility Study Measuring Psychedelic Effects on the Brain

Cybin Selects Generalized Anxiety Disorder as Target Indication for Deuterated DMT Molecule CYB004

Cybin Inc. Outlines Upcoming Priorities and Milestones for Its Clinical Development Programs

High number of new and inexperienced directors

Cybin Inc. Provides Progress Update on Its Cyb004-E Phase 1 Trial

Cybin Achieves Research and Development Milestones Ahead of Projected Timelines

Cybin Inc. Announces First Participants Dosed in Its Phase 1/2a Trial of CYB003 for the Treatment of Major Depressive Disorder

Cybin Inc. and Clinilabs Drug Development Corporation Announces U.S. Drug Enforcement Agency Grant A Schedule I License to Support the First-In-Human Phase 1/2A Clinical Trial of CYB003

Cybin Inc. Announces Clinilabs Drug Development Corporation Begins Enrollment for Phase 1/2A Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder

Independent Director recently bought US$56k worth of stock

Cybin Inc. Receives Fda Ind Clearance for Its Phase 1/2A Clinical Trial Evaluating Cyb003 for the Potential Treatment of Major Depressive Disorder

Cybin Inc., Annual General Meeting, Aug 15, 2022

Cybin Receives Institutional Review Board Approval for Its Phase 1/2A Clinical Trial Evaluating Cyb003 for the Treatment of Major Depressive Disorder

Cybin Acquires DMT Clinical Study from Entheon Biomedical

Cybin Inc. Submits IND Application to FDA for its Phase 1/2a First-In-Human Trial of CYB003 for Treatment of Major Depressive Disorder

Cybin and Kernel Announce Results from Kernel Flow Piloting of Feasibility Study Measuring Ketamine's Effects on the Brain

Cybin Inc. Announces CYB003 Poster to be Presented at the ‘From Research to Reality’ Global Summit on Psychedelic-Assisted Therapies and Medicine

High number of new and inexperienced directors

Cybin Inc. Announces Positive CYB004 Data Demonstrating Significant Advantages Over Intravenous and Inhaled DMT

Cybin Announces Initiation of Kernel Flow® Feasibility Study Measuring Psychedelic Effects on the Brain

High number of new and inexperienced directors

Cybin Announces Successful Completion of in Vivo Preclinical Studies for Its Deuterated Psilocybin Analog CYB003 Supporting Advancement into Phase 1/2a Clinical Trial

Cybin Inc. to Report Q3, 2022 Results on Feb 10, 2022

Institutional Review Board Grants Approval for Cybin Inc.'s Feasibility Study Using Kernel Flow Technology to Measure Psychedelic Effects on the Brain

Cybin Announces FDA Investigational New Drug and Institutional Review Board Approvals for A Co-Funded Phase 2 Clinical Trial to Treat Frontline Clinicians Experiencing Covid-Related Distress

Chief Operating Officer recently bought US$97k worth of stock

Cybin Awards Grant for Psychedelic Treatment Clinic At Lenox Hill Hospital to Benefit Underserved Communities

Chief Legal Officer recently bought US$54k worth of stock

Cybin Files Two Additional International Patent Applications in Support of the Company’S Research Phase Programs

Cybin Inc. Deleted from Other OTC

Cybin Files its 13th Patent Application

Cybin Announces Completion of Its 51St Pre-Clinical Psychedelic Molecule Study

Cybin Launches EMBARK and Co-Sponsors First Clinical Trial to Treat Frontline Clinicians Experiencing COVID-Related Burnout and Distress with Psychedelic-Assisted Psychotherapy

Cybin Inc. Files an International Patent Application Further Strengthening Its Psychedelic Derivative Drug Development Candidates Across 153 Global Jurisdictions